CDK4/6 inhibitor abemaciclib induces atypical cell-death with vacuolar formation by impairing lysosomal functions

被引：0
|
作者：
Hino, Hirotsugu [1 ]
Kazama, Hiromi [2 ]
Moriya, Shota [2 ]
Takano, Naoharu [2 ]
Hiramoto, Masaki [2 ]
Miyazawa, Keisuke [2 ]
机构：
[1] Nihon Univ, Div Anat Sci, Dept Funct Morpho, Sch Med, Tokyo, Japan
[2] Tokyo Med Univ, Dept Biochem, Tokyo, Japan
来源：
CANCER SCIENCE | 2021年 / 112卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PJ16-4-3
引用
收藏
页码：900 / 900
页数：1
相关论文
共 50 条
  • [41] Decreased Rab31 induces cancer stemness and CDK4/6 inhibitor resistance
    Hou, Xinfeng
    Hayashi, Takanori
    Mizutani, Yasuyoshi
    Okada, Seiji
    Suzuki, Motoshi
    Shimono, Yohei
    CANCER SCIENCE, 2024, 115 : 2124 - 2124
  • [42] Abemaciclib induces atypical cell death in cancer cells characterized by formation of cytoplasmic vacuoles derived from lysosomes
    Hino, Hirotsugu
    Iriyama, Noriyoshi
    Kokuba, Hiroko
    Kazama, Hiromi
    Moriya, Shota
    Takano, Naoharu
    Hiramoto, Masaki
    Aizawa, Shin
    Miyazawa, Keisuke
    CANCER SCIENCE, 2020, 111 (06) : 2132 - 2145
  • [43] HR-positive, HER2-negative Breast Cancer Prolongation of Survival by the CDK4 & 6 Inhibitor Abemaciclib
    Schmale, Ine
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (12) : 690 - 691
  • [44] Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma
    Rader, JulieAnn
    Russell, Mike R.
    Hart, Lori S.
    Nakazawa, Michael S.
    Belcastro, Lili T.
    Martinez, Daniel
    Li, Yimei
    Carpenter, Erica L.
    Attiyeh, Edward F.
    Diskin, Sharon J.
    Kim, Sunkyu
    Parasuraman, Sudha
    Caponigro, Giordano
    Schnepp, Robert W.
    Wood, Andrew C.
    Pawel, Bruce
    Cole, Kristina A.
    Maris, John M.
    CLINICAL CANCER RESEARCH, 2013, 19 (22) : 6173 - 6182
  • [45] Cdk4/6 inhibitor Abemaciclib overcomes resistance to BET inhibitor in leukemic cells with MLL-AF5q31 fusion gene
    Amari, Keigo
    Toda, Yuki
    Hosogi, Shigekuni
    Imamura, Toshihiko
    Ashihara, Eishi
    CANCER RESEARCH, 2020, 80 (16)
  • [46] Successful continuance of CDK4/6 inhibitor treatment with palbociclib after abemaciclib-induced hepatotoxicity in breast cancer: a case report
    Ozawa, Yuki
    Fujimiya, Tatsuhiro
    Shimada, Akihiko
    Okazawa, Akira
    Kusano, Junichi
    Yamamoto, Ryusei
    Hyasashi, Seiichi
    ANTI-CANCER DRUGS, 2024, 35 (01) : 89 - 92
  • [47] CDK4/6 inhibitor palbociclib suppresses IgE-mediated mast cell activation
    Yi-Bo Hou
    Kunmei Ji
    Yue-Tong Sun
    Li-Na Zhang
    Jia-Jie Chen
    Journal of Translational Medicine, 17
  • [48] Optimizing the combination of the CDK4/6 inhibitor palbociclib and paclitaxel using cell cycle analysis
    Spencer, Jade A.
    Race, Amanda D.
    Cooper, Patricia A.
    Shnyder, Steven D.
    Loadman, Paul M.
    Twelves, Christopher J.
    CANCER RESEARCH, 2020, 80 (16)
  • [49] Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines
    Digiacomo, Graziana
    Fumarola, Claudia
    La Monica, Silvia
    Bonelli, Mara A.
    Cretella, Daniele
    Alfieri, Roberta
    Cavazzoni, Andrea
    Galetti, Maricla
    Bertolini, Patrizia
    Missale, Gabriele
    Petronini, Pier Giorgio
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [50] CDK4/6 inhibitor palbociclib suppresses IgE-mediated mast cell activation
    Hou, Yi-Bo
    Ji, Kunmei
    Sun, Yue-Tong
    Zhang, Li-Na
    Chen, Jia-Jie
    JOURNAL OF TRANSLATIONAL MEDICINE, 2019, 17 (01)
12345